Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
KEYNOTE-603
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
- NCT03313778 ↗
- Active, not recruiting
- ModernaTX, Inc.
- Focused
We haven't built an HCP commentary report on KEYNOTE-603 (mRNA-4157, pembrolizumab and 1 more) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-603 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Solid Tumors
- Interventions
- mRNA-4157; Pembrolizumab; SoC Treatment
- Arms
- Part A: Dose Escalation and Dose Expansion · Experimental
- Part B: Dose Escalation and Dose Expansion · Experimental
- Part A2: Dose Expansion · Experimental
- Part C: Dose Expansion · Experimental
- Part D: Dose Expansion · Experimental
- Part E1: Dose Expansion · Experimental
- Part E2: Dose Expansion · Experimental
- Part E3: Dose Expansion · Experimental
- Enrollment
- 161
- Primary outcomes
- Number of Participants with Adverse Events
- Sponsor
- ModernaTX, Inc. with Merck Sharp & Dohme LLC
- Start
- Aug 14, 2017
- Primary completion
- Nov 21, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03313778 · updated Sep 3, 2026
Publications
linked from the registry- Berraondo P, Cuesta R, Sanmamed MF, Melero I. Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines. Cancer Discov. 2024 Nov 1;14(11):2021-2024. doi: 10.1158/2159-8290.CD-24-1196. PubMed 39485256